Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to Strong-Buy Rating

Elanco Animal Health (NYSE:ELAN) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Monday.

ELAN has been the topic of several other research reports. Morgan Stanley increased their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. Stifel Nicolaus increased their price target on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. UBS Group upped their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $23.78.

Elanco Animal Health Trading Up 1.5%

NYSE ELAN opened at $24.54 on Monday. The stock has a market cap of $12.19 billion, a PE ratio of 409.07, a PEG ratio of 3.41 and a beta of 1.87. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $24.84. The company’s 50-day moving average price is $22.50 and its 200-day moving average price is $19.71. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Equities research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Activity

In other news, insider Rajeev A. Modi bought 4,500 shares of the stock in a transaction on Thursday, December 11th. The stock was bought at an average cost of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the purchase, the insider directly owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Lawrence Erik Kurzius purchased 10,000 shares of the business’s stock in a transaction on Friday, December 12th. The stock was purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director directly owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 43,450 shares of company stock valued at $937,883 over the last 90 days. 0.89% of the stock is currently owned by corporate insiders.

Institutional Trading of Elanco Animal Health

Institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Elanco Animal Health during the 1st quarter valued at about $2,065,000. Goldman Sachs Group Inc. grew its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Empowered Funds LLC increased its holdings in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after acquiring an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after purchasing an additional 76,408 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in Elanco Animal Health by 66.6% in the 2nd quarter. Parallel Advisors LLC now owns 6,432 shares of the company’s stock worth $92,000 after purchasing an additional 2,572 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.